A phase I of MSLN-targeting CAR T cells demonstrated anti-tumor activity in pancreatic ductal carcinoma, ovarian cancer, and malignant mesothelioma (NCT03054298 and NCT03323944). This evidence concerns the gene MSLN and ovarian carcinoma.